Payment overview · 2025
General Payments
$3,964.16
107 reported records · 37 companies
Healthcare provider profile · identity verified
Fielding Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · EAST HARTFORD, CT · NPI 1346336237
Verified facts
What the public records show
CMS Open Payments records show Fielding Johnson, M.D. received $3,964.16 in general payments during 2025 across 107 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $499.14 | 12.6% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $435.12 | 11.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $400.96 | 10.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $350.25 | 8.8% | 14 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $280.48 | 7.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $201.91 | 5.1% | 9 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $179.62 | 4.5% | 4 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $160.24 | 4.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $146.61 | 3.7% | 3 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $127.25 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $127.15 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.78 | 3.1% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $88.78 | 2.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.70 | 1.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.51 | 1.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $63.06 | 1.6% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $62.40 | 1.6% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $52.32 | 1.3% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $52.21 | 1.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.03 | 1.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.99 | 1.1% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $44.04 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.69 | 0.8% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $29.05 | 0.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $27.53 | 0.7% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $25.16 | 0.6% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $24.37 | 0.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.09 | 0.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.75 | 0.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.58 | 0.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.35 | 0.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.82 | 0.5% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $19.20 | 0.5% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $18.38 | 0.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.32 | 0.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.70 | 0.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.62 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,964.16 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $465.81 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $435.12 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $280.48 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $277.55 | 11 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $273.47 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $201.91 | 9 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $179.62 | 4 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $160.24 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $160.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $160.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $160.24 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $146.61 | 3 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $127.25 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $127.15 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $112.32 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $106.54 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $94.53 | 4 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $88.78 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $85.43 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.51 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $63.06 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $62.40 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $52.32 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $52.21 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $48.25 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.99 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $44.04 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.69 | 3 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.17 | 2 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 184 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
184 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 52 |
| Gabapentin | Gabapentin | 204 | 33 |
| Trazodone Hcl | Trazodone Hcl | 201 | 26 |
| Montelukast Sodium | Montelukast Sodium | 199 | 48 |
| Metformin Hcl | Metformin Hcl | 194 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 184 | 47 |
| Lisinopril | Lisinopril | 174 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 35 |
| Divalproex Sodium | Divalproex Sodium | 161 | 18 |
| Eliquis | Apixaban | 158 | 16 |
| Jardiance | Empagliflozin | 145 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 111 | 13 |
| Furosemide | Furosemide | 103 | 21 |
| Prednisone | Prednisone | 101 | 24 |
| Sertraline Hcl | Sertraline Hcl | 99 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 95 | 31 |
| Famotidine | Famotidine | 93 | 13 |
| Meloxicam | Meloxicam | 92 | 21 |
| Mirtazapine | Mirtazapine | 91 | 14 |
| Humalog | Insulin Lispro | 87 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 87 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 18 |
| Mometasone Furoate | Mometasone Furoate | 81 | 23 |
| Losartan Potassium | Losartan Potassium | 78 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 15 |
| Tradjenta | Linagliptin | 77 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 74 | 21 |
| Alprazolam | Alprazolam | 71 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 69 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 68 | 17 |
| Omeprazole | Omeprazole | 68 | 13 |
| Xarelto | Rivaroxaban | 68 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 18 |
| Methocarbamol | Methocarbamol | 59 | 11 |
| Clonidine Hcl | Clonidine Hcl | 58 | suppressed |
| Clonazepam | Clonazepam | 56 | 11 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Trulicity | Dulaglutide | 55 | suppressed |
| Haloperidol | Haloperidol | 54 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 11 |
| Potassium Chloride | Potassium Chloride | 50 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 21 |
| Ingrezza | Valbenazine Tosylate | 49 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 11 |
| Risperidone | Risperidone | 47 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Simvastatin | Simvastatin | 44 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 41 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Carvedilol | Carvedilol | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Oxycontin | Oxycodone Hcl | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Nystatin | Nystatin | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Enulose | Lactulose | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 15 |
| Glipizide | Glipizide | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Betamethasone Valerate | Betamethasone Valerate | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,964.16 · 107 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, ACTHAR, AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BEVESPI AEROSPHERE, BREZTRI, CAPLYTA, CHARTIS CATHETER, CRYSVITA, Cologuard Collection Kit, DUPIXENT, EVENITY, FREESTYLE LIBRE 3, Filspari, GLASSIA, GLYCATE, GVOKE HYPOPEN, INGREZZA, JARDIANCE, Korlym, MYCAPSSA, NUCALA, NUZYRA, OFEV, OPSUMIT, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PROLIA, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, SHINGRIX, SYNTHROID, TERIPARATIDE, TRELEGY ELLIPTA, Tymlos, UBRELVY, UPTRAVI, VRAYLAR, WAKIX, XIFAXAN, YUPELRI, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, t:slim X2 Insulin Pump with Control-IQ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error